Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.008E-15 | 1.961E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.143E-10 | 2.240E-06 | ALOX15, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, XDH |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 7.512E-10 | 2.337E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 7.512E-10 | 2.337E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.779E-09 | 3.875E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 3.442E-09 | 5.765E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PTGS1 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.894E-09 | 7.690E-06 | CYP1A2, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 6.926E-09 | 8.378E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PTGS1 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.057E-08 | 1.129E-05 | AKR1B1, AKR1B10, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 6.917E-08 | 5.793E-05 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.760E-07 | 1.369E-04 | CYP1A2, CYP2C19, CYP2C9 |
MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 1.356E-06 | 8.438E-04 | SLC28A1, SLC28A3 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.934E-06 | 1.138E-03 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 2.512E-06 | 1.436E-03 | CASP1, CASP7, MAPT, XDH |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.571E-06 | 1.436E-03 | CYP1A2, CYP2D6, CYP3A4 |
BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 4.066E-06 | 1.967E-03 | SLC28A1, SLC28A3 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.066E-06 | 1.967E-03 | CYP2D6, CYP3A4 |
BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 4.066E-06 | 1.967E-03 | SLC28A1, SLC28A3 |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.892E-05 | 8.239E-03 | AKR1B1, AKR1B10, XDH |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.472E-10 | 7.510E-09 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.341E-08 | 5.680E-07 | CYP2C9; CDA; AKR1B10; CYP1A2; ALOX15; AKR1B1; TK1; CYP2C19; CYP3A4; XDH; PTGS1 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.352E-08 | 3.448E-07 | CYP2C9; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.563E-07 | 1.993E-06 | CYP2C9; CYP2D6; ALOX15; CYP2C19; PTGS1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.100E-07 | 2.142E-06 | CDA; TK1; CYP3A4; XDH |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 7.092E-07 | 6.028E-06 | CYP2C9; ALOX15; CYP2C19; PTGS1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.372E-06 | 9.997E-06 | CYP2C9; CYP2D6; CYP1A2; CYP3A4 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.190E-06 | 1.396E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.539E-05 | 2.825E-04 | CYP2C9; CYP1A2; CYP3A4 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.876E-03 | 5.893E-03 | TSHR; PTGS1 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.810E-03 | 5.893E-03 | CASP7; CASP1 |
hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 2.080E-03 | 5.893E-03 | AKR1B10; AKR1B1 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 7.783E-04 | 2.835E-03 | AKR1B10; AKR1B1 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.396E-04 | 2.293E-03 | AKR1B10; AKR1B1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.011E-03 | 5.893E-03 | CYP1A2; CYP3A4 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 6.144E-04 | 2.410E-03 | AKR1B10; AKR1B1 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.336E-03 | 8.954E-03 | CASP7; CASP1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.118E-02 | 2.715E-02 | CASP7; LMNA |
hsa00240 | Pyrimidine metabolism_Homo sapiens_hsa00240 | 6.428E-03 | 1.639E-02 | CDA; TK1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.581E-02 | 3.664E-02 | CASP7; MAPT |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.703E-04 | 7.893E-04 | CA12; CA9 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.262E-05 | 7.154E-05 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TK1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; CA9; TK1; CDA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
NA: NA | Rheumatold arthritis | NA | PTGS1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; AKR1B1 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; CA9; TK1 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TK1 |
C00-D49: Neoplasms | Prostate cancer | C61 | TK1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | TRPA1; PTGS1 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | TK1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |